Issue Date: September 9, 2026
Issued by: Center for Drug Evaluation and Research
Topic(s): Compounding
Status: Final
Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a guidance for industry titled “Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates.” This guidance describes the FDA’s regulatory and enforcement priorities regarding the compounding of certain starter parenteral nutrition drug products for neonates by outsourcing facilities and by State-licensed pharmacies and Federal facilities that are not registered with FDA as outsourcing facilities. This guidance is being published for immediate implementation due to the expected market exit of the predominant source of certain starter parenteral nutrition drug products for neonates in the United States.
Download the Guidance Document
